Physician profile
Jeevan Errabolu
NPI 1215165543
$3,512.34
in general payments reported to CMS, 2019-2025
37 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $404 · 2021: $772 · 2022: $833 · 2023: $369 · 2024: $279 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $491.77 | 2019-2025 | |
| Lilly USA, LLC | $328.70 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $305.48 | 2021-2024 | |
| Novo Nordisk INC | $269.74 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $231.55 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $158.90 | 2019-2025 | Veozah |
| Mylan Specialty L.P. | $153.84 | 2019-2022 | |
| Amgen INC. | $144.87 | 2019-2025 | Otezla, Repatha, Otezla |
| Horizon Therapeutics Plc | $128.30 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $102.12 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $88.98 | 2019-2022 | |
| Medtronic Vascular, INC. | $88.18 | 2019 | |
| Abbott Laboratories | $88.12 | 2020-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $87.01 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $76.79 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeevan Errabolu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.